Biotech Entrepreneur, CEO, Professor, Physician-Scientist, Therapeutics Designer & Developer
I thoroughly enjoyed joining my colleagues and peers at #CTS2024. We discussed our journey in navigating the complexities of developing a potentially transformative treatment for wet AMD and other retinal diseases. Thank you to CTS Retina for organizing a stellar conference. We also shared progress and strong efficacy data from our PRISM trial evaluating 4D-150 in the highest need patients. Stay tuned as we look forward to sharing interim results from our Population Extension cohort in the broader wet AMD population at the ASRS – American Society of Retina Specialists Annual Scientific Meeting on July 17, 2024.
Our team was out in force this past weekend at #CTS2024! Our Co-founder and CEO, David Kirn, MD, and CMO, Robert Kim, M.D., provided a company overview and participated in panels moderated by Arshad M. Khanani and Peter Kaiser discussing key challenges in #clinicaltrial design and bringing new treatment options to market. Carl Danzig, M.D., also joined us from the Rand Eye Institute to present positive subgroup analysis data from our Phase 2 #PRISM trial of our #geneticmedicine, 4D-150, for the treatment of #wetAMD. Learn more here: https://lnkd.in/g_XUEbeB
Thank you David Kirn, MD for the opportunity to present this important data at CTS Retina 2024! I look forward to seeing what’s next at the ASRS – American Society of Retina Specialists meeting next month in Stockholm!
Director of Clinical Research at Sierra Eye Associates
1moThanks David Kirn, MD! It was a pleasure to have you, Robert Kim and the 4D Molecular Therapeutics team participate in CTS Retina 2024. Everyone learned a lot from you and Robert Kim on the panels. The new PRISM data presented by Carl Danzig is very exciting for our field! We appreciate the gold sponsorship by 4D Molecular Therapeutics and looking forward to seeing you/team at CTS 2025!